

Docket No.: 202617US0PCT



RECEIVED

NOV 14 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

# 12/B  
9/D  
11/21/02

IN RE APPLICATION OF:

:

Man S. CO, et al.

: ART UNIT: 1646

SERIAL NO.: 09/763,129

:

FILED: MAY 16, 2001

:

FOR: ANTITHROMBOTIC AGENT AND HUMANIZED ANTI VON WILLEBRAND  
FACTOR MONOCLONAL ANTIBODY

PRELIMINARY AMENDMENT AND REQUEST FOR RECONSIDERATION

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows:

IN THE CLAIMS

Please cancel Claims 1-17, 20, and 22.

Please amend the claims as shown in the marked-up sheets to read as follows:

18. (Amended) A method of treating a patient having or at risk of a thrombotic disease or atherosclerosis, comprising: administering to said patient an effective dose of a humanized immunoglobulin, wherein said humanized immunoglobulin comprises

(a) complementarity determining regions having amino acid sequences RFWMS (31-35), EVNPDNNTMNYTPSLKD (50-66) and PPYYGSYGGFAY (99-110), in the heavy